Vitamin B6 is the one compound in this matrix with a clean controlled trial behind it. Aspy et al. (2018) ran a double-blind, placebo-controlled study across roughly 100 participants: 240 mg of pyridoxine hydrochloride before sleep for five consecutive nights. The finding was narrow and specific. Participants recalled more dream content, with no change to vividness, bizarreness, emotional intensity, or colour. B6 appeared to act on remembering the dream rather than on the dream itself.
This run tested that at 240 mg for seven consecutive nights, taken in water immediately before sleep. No stacking, no induction techniques, no intention setting.
The recall effect did not reproduce. Recall averaged 3.1 against a personal baseline of 3.0 on nights with nothing. Two nights reached a 4, one dropped to a 2. That spread is indistinguishable from noise. There was also no front-loading: the higher scores landed on nights three and six, not in the first three days, which is where the earlier Ebben (2002) data would have predicted them.
The null half reproduced exactly. Vividness, narrative coherence, and emotional intensity each scored 3 on all seven nights, with no variation at all. Hypnagogic imagery sat at 1 for the entire week. Whatever else B6 does, it did not touch the character of the dreams, which is precisely what the trial reported.
Then night seven. Standing in a group of people inside a dream, the detail on their faces registered as too complete. That recognition produced lucidity, immediately followed by enough excitement to collapse the state and wake up. It was the eighth lucid dream of a lifetime and the first to arrive without any intention setting. This protocol deliberately excludes induction techniques so that anything observed can be attributed to chemistry rather than practice.
The reading that fits the data is unresolved rather than causal. It was a single event on the final night, on the worst sleep of the week, with the lowest recall score of the seven. The trial found no lucidity effect across a hundred participants. Set against that, one night proves nothing.
It is also the only measure that moved. Lucidity scored 4 against a baseline of 1, the largest single deviation anywhere in the week’s data. And Aspy’s own stated position is that reliable recall is the gateway to lucidity, which makes the pairing of a lucid event with a null recall result more puzzling rather than less.
B6 therefore enters the matrix flagged for lucidity and marked low impact: an unexplained single event, not a demonstrated effect. It warrants a second, longer run with a pre-registered lucidity count measured against an established personal base rate. Without that number, one event in seven nights cannot be separated from chance.
One safety note. 240 mg is roughly 185 times the adult daily requirement and well above the tolerable upper intake levels set in both the US and the EU. Sustained high intake causes sensory peripheral neuropathy, meaning tingling and numbness in the hands and feet. This run stopped at seven nights by design. It is not a protocol to copy.